PREPARE-IBD [COVID-19]
Research type
Research Study
Full title
PREPARE-IBD: Physician responses to disease flares and patient adaptation in relation to events in Inflammatory Bowel Disease during COVID-19 pandemic: A multi center cohort analysis.
IRAS ID
284920
Contact name
Shaji Sebastian
Contact email
Sponsor organisation
Hull University Teaching Hospital NHS Trust
Duration of Study in the UK
0 years, 3 months, 0 days
Research summary
Inflammatory Bowel Disease (IBD) comprises of two major chronic intestinal disorders, Crohn’s disease (CD) and Ulcerative Colitis (UC). Both diseases are characterised by a relapsing and remitting course with periods of active disease and periods of remission. In the It is estimated that approximately 550,000 patients in the UK are living with IBD.\nThe coronavirus disease (COVID-19) worldwide outbreak has led to unprecedented challenges for all healthcare systems, including IBD centres.\n\nThere is no data so far on the impact of development of COVID 19 in patients with IBD and the impact of IBD status on patients with COVID-19. For patients with IBD who are experiencing a flare in their disease, both physicians and patients are making adaptations to routine IBD flare management, including changes in traditional approaches/therapies but as yet, there is no data or evidence base to inform these changes. The outcomes in this group of patients from the IBD perspective are not yet known.\n\nThe management of IBD during the COVID-19 pandemic poses several additional challenges to IBD teams at all stages of the standard care pathway. There may be a higher thresh hold to admit IBD patients to hospitals with COVID-19 patients, particularly those with high risk features needing shielding. It has been well documented that patients themselves are reluctant for hospitalisation because of the understandable anxieties about transmission and hence may present much later than normal. The COVID-19 pandemic has an inevitable impact on IBD patients due to the need for shielding for high risk and this may impact on care patterns and monitoring.\n\nThere are considerable areas of uncertainty in relation to risk stratifying and managing CD and UC patients in the era of the COVID-19 pandemic and this will undoubtedly contribute to variability in practice patterns and potentially differences outcomes among these patients.\nThe purpose of this project will be to collect homogenous, detailed, longitudinal clinical, endoscopic and laboratory data from a retrospective cohort of IBD patients during the COVID-19 pandemic undergoing shielding due to flares and also following hospitalization. \n [Study relying on COPI notice]
REC name
N/A
REC reference
N/A